A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

NCT03068312 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: Ivacaftor
DRUG: Placebo

Sponsor

Vertex Pharmaceuticals Incorporated